Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ulus Ali Sanli
Safety and Efficacy of Regorafenib in Patients With Treatment-Refractory Metastatic Colorectal Cancer in Turkey: The Single-Arm, Open-Label REGARD Study
BMJ Open
Medicine
Related publications
Angiogenesis Genotyping and Clinical Outcome During Regorafenib Treatment in Metastatic Colorectal Cancer Patients
Scientific Reports
Multidisciplinary
The Cost–Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer (Mcrc) Who Have Progressed After Standard Therapies in Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy and Safety of Privigen®in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Results of a Prospective, Single-Arm, Open-Label Phase III Study (The PRIMA Study)
Journal of the Peripheral Nervous System
Medicine
Neuroscience
Neurology
A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
Patient Preference and Adherence
Pharmacology
Health Policy
Medicine
Toxicology
Social Sciences
Pharmaceutics
Trial Design of Phase IIIb, Open-Label, Single Arm Study to Evaluate Efficacy and Safety of Pasireotide LAR in Patients With Inadequately-Controlled Acromegaly Despite Treatment With First-Generation Somatostatin Analogues
Endocrine Abstracts
Efficacy, Safety and Pharmacokinetics of Subcutaneous Azacitidine in Chinese Patients With Higher Risk Myelodysplastic Syndromes: Results From a Multicenter, Single-Arm, Open-Label Phase 2 Study
Asia-Pacific Journal of Clinical Oncology
Medicine
Oncology
Thyroid Dysfunction and Ultrasonography Features in Patients With Metastatic Colorectal Cancer Treated With Regorafenib: Preliminary Results From a Single Centre Prospective Cohort Study
Endocrine Abstracts
Efficacy and Safety of TAS-116, an Oral Inhibitor of Heat Shock Protein 90, in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumour Refractory to Imatinib, Sunitinib and Regorafenib: A Phase II, Single-Arm Trial
European Journal of Cancer
Cancer Research
Oncology
